Involvement of P2X(7) purinergic receptor and MEK1/2 in interleukin-8 up-regulation by LL-37 in human gingival fibroblasts

J Periodontal Res. 2011 Jun;46(3):327-37. doi: 10.1111/j.1600-0765.2011.01346.x. Epub 2011 Feb 21.

Abstract

Background and objective: The antimicrobial peptide LL-37, derived from human neutrophils, can directly chemoattract leukocytes and up-regulate the expression of several immune-related genes in various cell types. In this study, we wanted to determine the immunoregulatory effect of LL-37 on interleukin-8 (IL-8) expression in human gingival fibroblasts (HGFs) and to characterize intracellular signaling pathway(s) and receptor(s) involved in IL-8 induction.

Material and methods: Cultured fibroblasts were treated with different concentrations of LL-37 or interleukin-1β (IL-1β), as a positive control, for specific periods of time in the presence or absence of various inhibitors. RT-PCR and real-time PCR were conducted to analyze the expression of IL-8 mRNA, and the IL-8 levels in cell-free culture media were measured using ELISAs. The MTT assay was performed to determine the cytotoxicity of LL-37.

Results: Nontoxic concentrations of LL-37 (up to 10 μm) and IL-1β significantly up-regulated the expression of IL-8 mRNA in a dose-dependent manner (p < 0.05). The IL-8 protein levels were consistently significantly elevated in conditioned media of LL-37-treated HGFs (p < 0.05). IL-8 up-regulation by LL-37 was completely abrogated by 20 μm U0126, consistent with transient phosphorylation of p44/42 MAP kinases. Moreover, pretreatment with Brilliant Blue G (a selective antagonist of the P2X(7) receptor) and the neutralizing antibody against P2X(7) blocked IL-8 up-regulation in a dose-dependent manner, consistent with expression of the P2X(7) receptor in HGFs.

Conclusion: These findings indicate that LL-37 induces IL-8 expression via the P2X(7) receptor and the MEK1/2-dependent p44/42 MAP kinases in HGFs, suggesting both direct and indirect involvement of LL-37 in neutrophil recruitment into an inflammatory site within diseased periodontal tissues.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Antibodies, Neutralizing / pharmacology
  • Antimicrobial Cationic Peptides
  • Butadienes / pharmacology
  • Cathelicidins / pharmacology*
  • Cells, Cultured
  • Culture Media
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Fibroblasts / drug effects*
  • Gingiva / cytology
  • Gingiva / drug effects*
  • Humans
  • Interleukin-1beta / pharmacology
  • Interleukin-8 / drug effects*
  • Interleukin-8 / metabolism
  • MAP Kinase Kinase 1 / antagonists & inhibitors
  • MAP Kinase Kinase 1 / physiology*
  • MAP Kinase Kinase 2 / antagonists & inhibitors
  • MAP Kinase Kinase 2 / physiology*
  • Mitogen-Activated Protein Kinase 1 / physiology
  • Mitogen-Activated Protein Kinase 3 / physiology
  • Neutrophil Infiltration / physiology
  • Nitriles / pharmacology
  • Phosphorylation
  • Purinergic P2X Receptor Antagonists / pharmacology
  • Receptors, Purinergic P2X7 / physiology*
  • Rosaniline Dyes / pharmacology
  • Up-Regulation / drug effects*

Substances

  • Anti-Bacterial Agents
  • Antibodies, Neutralizing
  • Antimicrobial Cationic Peptides
  • Butadienes
  • Cathelicidins
  • Culture Media
  • Enzyme Inhibitors
  • Interleukin-1beta
  • Interleukin-8
  • Nitriles
  • Purinergic P2X Receptor Antagonists
  • Receptors, Purinergic P2X7
  • Rosaniline Dyes
  • U 0126
  • MAP2K2 protein, human
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • MAP Kinase Kinase 1
  • MAP Kinase Kinase 2
  • MAP2K1 protein, human
  • coomassie Brilliant Blue